Xenetic Biosciences, Inc. (XBIO) News
Filter XBIO News Items
XBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XBIO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest XBIO News From Around the Web
Below are the latest news stories about XENETIC BIOSCIENCES INC that investors may wish to consider to help them evaluate XBIO as an investment opportunity.
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentFRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today ... |
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced ... |
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology ProgramXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has entered into a Clinical Trial Services ... |
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung MetastasisXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating ... |
Xenetic Biosciences Third Quarter 2024 Earnings: Misses ExpectationsXenetic Biosciences ( NASDAQ:XBIO ) Third Quarter 2024 Results Key Financial Results Revenue: US$614.2k (flat on 3Q... |
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial ResultsEstablishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications Ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors Strategic ... |
Xenetic Biosciences: Q3 Earnings SnapshotFRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Tuesday reported a loss of $437,000 in its third quarter. |
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma ModelsData presented at Society for Immunotherapy of Cancer (SITC) 2024 Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient ... |
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformCompany is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical ... |
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, ... |